IP Library Granted Patent US 11,608,328
Granted Patent B2
US 11,608,328 · App. 16/797,744 · Granted Mar 21, 2023

Chemical probes to identify anti-mycobacterial MmpL3 inhibitors

Inventors: E. Jeffrey North (Omaha, NE); Amitkumar Navinchandra Pandya (Omaha, NE); Mary C. Jackson (Fort Collins, CO); Wei Li (Fort Collins, CO); Mercedes Gonzalez-Juarrero (Fort Collins, CO)
Assignees: Creighton University; Colorado State University Research Foundation
C07D405/14C07F5/022G01N33/502
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,608,328
App. No.
16/797,744
Granted
Mar 21, 2023
Kind
B2
Abstract

The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.

Claims (50)

1. A compound of Formula I:

A-B-C

or a salt thereof, wherein:

A is a fluorescent detectable moiety selected from the group consisting of:

B is a linking group selected from the group consisting of:

—C(O)NH—(C 1-10 alkylene)-(5-6 membered heteroaryl)-(C 1-10 alkylene)-; and

—(C 1-10 alkylene)-C(O)NH—(C 1-10 alkylene)-(5-6 membered heteroaryl)-(C 1-10 alkylene)-; and

C is an MmpL3 inhibitor moiety selected from the group consisting of:

wherein:

X 1 is selected from the group consisting of C(O)NH and NHC(O)NH;

R 1 is C 5-10 cycloalkyl, which is optionally substituted by 1, 2, 3, or 4 independently selected C 1-4 alkyl groups; and

R 2 is C(O)C 1-4 alkoxy.

2. The compound of claim 1 , or a salt thereof, wherein B is —C(O)NH—(C 1-10 alkylene)-(5-6 membered heteroaryl)-(C 1-10 alkylene)-.

3. The compound of claim 1 , or a salt thereof, wherein the fluorescent detectable moiety is:

wherein refers to the bond between A and B.

4. The compound of claim 1 , or a salt thereof, wherein the fluorescent detectable moiety is:

wherein refers to the bond between A and B.

5. The compound of claim 1 , or a salt thereof, wherein B is

—(C 1-10 alkylene)-C(O)NH—(C 1-10 alkylene)-(5-6 membered heteroaryl)-(C 1-10 alkylene)-.

6. The compound of claim 1 , or a salt thereof, wherein B is a linking group selected from the group consisting of:

—C(O)NH—(C 1-6 alkylene)-(5-6 membered heteroaryl)-(C 1-3 alkylene)-; and

—(C 1-3 alkylene)-C(O)NH—(C 1-3 alkylene)-(5-6 membered heteroaryl)-(C 1-3 alkylene)-.

7. The compound of claim 1 , or a salt thereof, wherein B is a linking group selected from the group consisting of:

—C(O)NHCH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -triazolyl-CH 2 —; and

—CH 2 CH 2 C(O)NHCH 2 CH 2 CH 2 -triazolyl-CH 2 —.

8. The compound of claim 1 , or a salt thereof, wherein

X 1 is C(O)NH.

9. The compound of claim 1 , or a salt thereof, wherein X 1 is NHC(O)NH.

10. The compound of claim 1 , or a salt thereof, wherein R 1 is C 5-10 cycloalkyl, which is optionally substituted by 1, 2, or 3 independently selected C 1-4 alkyl groups.

11. The compound of claim 1 , or a salt thereof, wherein R 1 is selected from the group consisting of cyclooctyl, bicyclo[3.1.1]heptyl, and adamantyl, each of which is optionally substituted by 1, 2, or 3 methyl groups.

12. The compound of claim 1 , or a salt thereof, wherein R 2 is C(O)OCH 3 .

13. The compound of claim 1 , or a salt thereof, wherein:

A is a fluorescent detectable moiety selected from the group consisting of:

wherein refers to the bond between A and B;

B is a linking group selected from the group consisting of —C(O)NH—(C 1-6 alkylene)-(triazolyl)-(C 1-3 alkylene)- and —(C 1-3 alkylene)-C(O)NH—(C 1-3 alkylene)-(triazolyl)-(C 1-3 alkylene)-; and

C is an MmpL3 inhibitor moiety selected from the group consisting of:

wherein:

refers to the bond between B and C;

X 1 is selected from the group consisting of C(O)NH and NHC(O)NH;

R 1 is selected from the group consisting of cyclooctyl, bicyclo[3.1.1]heptyl, and adamantyl, each of which is optionally substituted by 1, 2, or 3 methyl groups; and

R 2 is C(O)OCH 3 .

14. The compound of claim 1 , or a salt thereof, wherein the compound of Formula I is a compound of Formula II, a compound of Formula III, or a compound of Formula IV:

or a salt thereof.

15. The compound of claim 1 , which is selected from the group consisting of:

or a salt thereof.

16. A composition, comprising a compound of claim 1 , or a salt thereof, and a carrier.

17. A method of identifying an inhibitor of MmpL3, comprising:

i) contacting a cell with a compound of claim 1 , or a salt thereof, to form a compound-MmpL3 complex in the cell;

ii) contacting the cell with a test compound; and

iii) measuring displacement of the compound from the compound-MmpL3 complex and formation of a test compound-MmpL3 complex in the cell.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 2, 2023
From: CREIGHTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065091/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: NORTH, E. JEFFREY; PANDYA, AMITKUMAR NAVINCHANDRA
To: CREIGHTON UNIVERSITY
Reel/Frame 061597/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2020
From: JACKSON, MARY C.; LI, WEI; GONZALEZ-JUARRERO, MERCEDES
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 053357/0514 →
Continuity (2)
Provisional Application 62808469 · Feb 21, 2019
Related Publication 20200331897A1 · Oct 22, 2020